Floatz logo

2-Bromo-?-ergocryptine

Familial Alzheimer Disease (FAD)

Kyoto UniversitySmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Familial Alzheimer Disease (FAD) cohort.

Asset / SponsorPhaseRating
LECANEMAB
Washington University School of Medicine
Phase 3BB
Immunoglobulin G1 [de-449-lysine], anti-(human tau protein) (human-Mus musculus monoclonal E2814 ?1-chain), disulfide with human-Mus musculus monoclonal E2814 .kappa.-chain, dimer
Washington University School of Medicine
Phase 2/3B
Remternetug
Washington University School of Medicine
Phase 2/3B
Solanezumab
Washington University School of Medicine
Phase 2/3CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN 1-40-.BETA.-AMYLOID/HUMAN 1-42-.BETA.-AMYLOID) (HUMAN MONOCLONAL .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL .KAPPA.-CHAIN, DIMER
Washington University School of Medicine
Phase 2/3CC

Same molecule, other indications

2-Bromo-?-ergocryptine is also rated in:

Parkinson diseaseDormant
BB
Indicative ·
69 / 100
View asset →
prediabetes syndromeDormant
BB
Indicative ·
65 / 100
View asset →
eating disorderDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →